Acetaminophen increases blood pressure in patients with coronary artery disease

Circulation

Volumn 122, Issue 18, 2010, Pages 1789-1796

  Sudano, Isabella ^a   Flammer, Andreas J ^a   Périat, Daniel ^a   Enseleit, Frank ^a   Hermann, Matthias ^a   Wolfrum, Mathias ^a   Hirt, Astrid ^a   Kaiser, Priska ^a   Hurlimann, David ^a   Neidhart, Michel ^a   Gay, Steffen ^d   Holzmeister, Johannes ^a   Nussberger, Juerg ^b   Mocharla, Pavani ^a   Landmesser, Ulf ^a   Haile, Sarah R ^c   Corti, Roberto ^a,d   Vanhoutte, Paul M ^e   Lüscher, Thomas F ^a,d   Noll, Georg ^a,d   Ruschitzka, Frank ^a,d   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Institute for Social and Preventive Medicine   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

acetaminophen; blood pressure; coronary disease; endothelium

Indexed keywords

ALDOSTERONE; PARACETAMOL; PLACEBO; PROSTAGLANDIN E2; RENIN; THROMBOXANE B2;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEART RATE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; STEM CELL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE FUNCTION; VASODILATATION;

ACETAMINOPHEN; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CIRCADIAN RHYTHM; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; PROSPECTIVE STUDIES; RISK FACTORS; VASODILATION;

EID: 78349308026     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.956490     Document Type: Article

References (45)

1. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use ofnonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
2. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359:285-292.
3. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167:394-399.
4. Montgomery B. Does paracetamol cause hypertension? BMJ. 2008;336: 1190-1191.
5. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk ofcardiovascular events. Circulation. 2006; 113:1578-1587.
6. Chalmers JP, West MJ, Wing LM, Bune AJ, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A. 1984;6:1077-1093.
7. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy ofantihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987;107:628-635.
8. Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15:e372-e382.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamo-poulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25: 1105-1187.
10. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
11. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function and dysfunction, part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:7-17.
12. Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Kunzler P, Enseleit F, Periat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008; 117:2262-2269.
13. Gemignani V, Bianchini E, Faita F, Giannarelli C, Plantinga Y, Ghiadoni L, Demi M. Ultrasound measurement ofthe brachial artery flow-mediated dilation without ECG gating. Ultrasound Med Biol. 2008;34:385-391.
14. Gemignani V, Faita F, Ghiadoni L, Poggianti E, Demi M. A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images. IEEE Trans Med Imaging. 2007;26:393-404.
15. Nussberger J, de Gasparo M, Juillerat L, Guyenne TT, Mooser V, Waeber B, Brunner HR. Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A. Clin Exp Hypertens A. 1987;9:1353-1366.
16. Nussberger J, Waeber B, Brunner HR, Burris JF, Vetter W. Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods. J Lab Clin Med. 1984;104:789-796.
17. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111: 2356-2363.
18. Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N, Doerries C, Horvath T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U. Oxidant stress impairs in vivo reendotheli-alization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor- gammaagonistrosiglitazone. Circulation. 2007;116:163-173.
19. Flammer AJ, Hermann F, Sudano I, Spieker L, Hermann M, Cooper KA, Serafini M, Luscher TF, Ruschitzka F, Noll G, Corti R. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation. 2007;116:2376-2382.
20. Senn S. Cross-Over Trials in Clinical Research. Chichester, UK: Wiley; 1993.
21. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8:7-20.
22. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007;370:2138-2151.
23. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005; 165:490-496.
24. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
25. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential ther-apeutic implications. Ann Med. 2005;37:74-85.
26. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46: 500-507.
27. Palmieri EA, Palmieri V, Innelli P, Arezzi E, Ferrara LA, Celentano A, Fazio S. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men. Eur J Appl Physiol. 2005;94:113-117.
28. Kurth T, Hennekens CH, Sturmer T, Sesso HD, Glynn RJ, Buring JE, Gaziano JM. Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med. 2005;165:1903-1909.
29. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma pre-vention. N Engl J Med. 2005;352:1071-1080.
30. Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens. 2006;24:1457-1469.
31. Montgomery BD. Analgesic use and risk of hypertension: concern about bias. Arch Intern Med. 2007;167:2368-2369.
32. Grover SA, Coupal L, Zowall H. Treating osteoarthritis with cyclooxy-genase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension. 2005;45:92-97.
33. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease, part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
34. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781-786.
35. Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther. 2005;12:46-55.
36. Mattammal MB, Zenser TV, Brown WW, Herman CA, Davis BB. Mechanism of inhibition of renal prostaglandin production by acetaminophen. J Pharmacol Exp Ther. 1979;210:405-409.
37. Bippi H, Frolich JC. Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man. Br J Clin Pharmacol. 1990;29:305-310.
38. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351:1709-1711.
39. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature. 1972;240:410-411.
40. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet. 2003;361:981-982.
41. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acet-aminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci US A. 2002;99:13926-13931.
42. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22:383-390.
43. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Parac-etamol: new vistas of an old drug. CNS Drug Rev. 2006;12:250-275.
44. Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, Spieker LE, Frey D, Hermann M, Riesen W, Neidhart M, Michel BA, Hellermann JP, Gay RE, Luscher TF, Gay S, Noll G, Ruschitzka F. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol. 2005;45:461-464.
45. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.